Navigation Links
Rockland Immunochemicals Awarded Phase I SBIR Funding to Develop Novel Agents for Cancer Diagnosis and Targeted Therapy

Gilbertsville, PA (PRWEB) October 28, 2013

Rockland Immunochemicals Inc. today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute, National Institutes of Health (NCI/NIH) to develop nanoprobes for in vivo imaging of cancer cells and tumors that express one of the three important cancer therapeutic targets: EGFR, Her2 and Mesothelin. This project is a joint collaboration between Rockland and Abzyme Therapeutics with in vivo imaging consultants from Yale University and the University of Pittsburgh.

Medical imaging is a key component in the clinical management of cancer patients. Cancer imaging agents are used in conjunction with medical imaging equipment and, by highlighting the contrast between normal and malignant tissues, allow the collection of information on cancer presence and progression. Developing novel imaging agents that can be used for imaging and targeted radiotherapy of cancer would greatly enhance the efficacy of the cancer patient management and help usher in a new era of personalized cancer therapy.

According to market research firm Markets and Markets, the global diagnostic imaging market, which stood at $20.7 billion in 2010, is expected to swell to $26.6 billion by 2016. This expected rise is attributed to an aging population, increasing awareness about preventive care, and advancements in the field.

In Phase 1, Rockland and Abzyme Therapeutics will develop, label, and characterize high-affinity single domain antibodies (sdAbs) against EGFR, Her2 and Mesothelin. Under the terms of this grant, Abzyme Therapeutics will develop single domain antibodies and Rockland will be responsible for bioconjugation and in vivo characterization.

“Despite significant scientific progress, very few cancer imaging agents are available in the clinic,” commented Carl A Ascoli, PhD, Laboratory Director at Rockland Immunochemicals. “The size, ease of manufacture, and condition-resistant nature of sdAbs make them the best choice as capture molecules. We expect that our sdAb imaging agents will have superiority over other agents designed for in vivo and in situ biodetection and diagnosis.”

“In these times of shrinking government investment in research, this SBIR grant validates Rockland’s business model of collaboration with leading academic institutions to aggregate, develop and commercialize technologies that will ultimately benefit humanity,” continued Jim Fendrick, President and CEO of Rockland Immunochemicals. “This research is in line with the company’s expertise in antibodies and antibody based tools. We are confident that this collaboration will generate significant innovation and that the results will have great scientific and commercial applications.”

In the planned Phase II portion of this project, the key antibodies will be radionuclide labeled and characterized using PET scanners in collaboration with Yale University and University of Pittsburg. Radionuclide labeled antibodies specific to cancer cells can be used not only as in vivo imaging agents but also for targeted cancer therapy.

About Rockland Immunochemicals
Rockland Immunochemicals has supported the academic, biopharma and diagnostic industries with antibodies and antibody based tools™ for basic research, assay development and preclinical studies for over 50 years. With facilities in Pennsylvania, Rockland manufactures over 10,000 products ideally suited for integration into critical assays such as western blotting, immunohistochemistry (IHC), immunofluorescence microscopy (IF), ELISA and FLOW cytometry. Additional information about Rockland Immunochemicals’ Life Science Tools and services can be found on the company’s website at

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. $9 million grant awarded to UH to study, treat learning disabilities
3. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
4. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
5. Grant awarded to help improve problem-solving skills for deaf and hard-of-hearing students
6. Southeast program to fight diabetes awarded nearly $10 million by HHS
7. Clemson professor awarded nearly $600,000 4-year grant to study language of plants
8. 29 Johns Hopkins stem cell researchers awarded funding
9. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
10. FirstVitals Health and Wellness, Inc. awarded $4 Million CMS Innovation Grant for Unique Telehealth Diabetes Progam Focused on Glycemic Control and Prevention of Diabetic Foot Complications
11. EMBO Gold Medal 2012 awarded to Jiri Friml
Post Your Comments:
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
Breaking Medicine Technology: